Following a September 30 status conference, the first Benicar multidistrict litigation lawsuit has been scheduled for trial in late 2016, reports the New Jersey Law Journal.
The litigation, overseen by District Judge Michael Schneider in the U.S. District Court for the District of New Jersey, already includes over 1,100 Benicar lawsuits. These have been filed by patients who claim Daiichi Sankyo’s hypertension drug Benicar caused ...
continue reading...Benicar lawsuits consolidated in the New Jersey multidistrict litigation now exceed 1,000, and as more pour in, Benicar plaintiffs continue to ask: What took the U.S. Food and Drug Administration (FDA) so long to warn patients about the drug’s severe gastrointestinal side effects?
Daiichi Sankyo’s Benicar was approved by the FDA in 2002 to help treat patients with high blood pressure. It quickly became one of ...
continue reading...An Ohio woman has filed a new Benicar lawsuit alleging Daiichi Sankyo’s blood-thinning drug caused her chronic diarrhea and dehydration. The plaintiff has accused Benicar’s manufacturers of downplaying or concealing certain dangerous side effects associated with the medication. The new lawsuit will join over 200 similar Benicar lawsuits that have been consolidated in a multidistrict litigation before the U.S. District Court for the District of New Jersey.
Benicar, ...
continue reading...
A July 17 joint report filed before the U.S. District Court for the District of New Jersey indicates that the number of Benicar lawsuits included in multidistrict litigation (MDL) 2606 now stands at 205. This is a whopping 135 more than the 70 Benicar lawsuits reported at an MDL conference in June, and 190 more than the initial 15 federal cases centralized in March.
Benicar, pharmaceutical giant ...
continue reading...The U.S. Judicial Panel on Multidistrict Litigation has ruled to consolidate lawsuits alleging that Benicar, Daiichi Sankyo’s brand-name olmesartan, can cause serious gastrointestinal issues. According to Reuters, the panel handed down its ruling after a March 26 hearing in the U.S. District Court for the Southern District of California.
Benicar was approved by the U.S. Food and Drug Administration (FDA) in 2002 for use as a blood pressure medication. ...
continue reading...Pharmaceutical giant Daiichi Sankyo, maker of the blood pressure drug Benicar, will begin laying off 16 percent of its U.S. staff at its headquarters in Parsippany, NJ. The company has also announced plans to cut even more staff starting in mid-April.
Sankyo’s most recent nine-month report indicates that the company’s North American revenue increased 6 percent from the previous year but fell by 1.5 percent in terms of ...
continue reading...
